Vape manufacturing quality control becomes useful when an RFQ turns broad supplier assurances into written, verifiable requirements. This buyer glossary helps licensed U.S. businesses compare OEM, ODM, private-label, and wholesale discussions by defining the records, test conditions, acceptance criteria, and change controls behind commonly used quality terms.
>
Build a buyer-owned quality brief
An RFQ should make “quality” comparable. Attach the product configuration, artwork revision, intended accessories, evaluation scope, and requested release records. Ask every bidder to respond to the same attachment set.
Assign roles early: brand owner, supplier, document custodian, release authority, and importer of record where applicable. FDA states that a party that makes, modifies, assembles, labels, repacks, relabels, or imports a tobacco product may be a tobacco product manufacturer. Its overview identifies applicable obligations that can include establishment registration, product listing, and a pathway to market a new tobacco product. Read FDA’s manufacturing overview. This allocation does not replace product-specific legal review.
Use Autosweave Labs’ quality resources with the vapor-hardware supplier due-diligence checklist to tie each response to the quoted configuration—not a generic compliance packet.
Buyer glossary for vape manufacturing quality control
Approved sample (or golden sample). A mutually identified reference unit and cosmetic standard. Record its configuration, revision, date, photographs, and permitted variation. It is a comparison reference, not automatic approval of future production.
Bill of materials (BOM). The controlled list of parts, materials, and approved alternates for the quoted configuration. Request the BOM revision and the method for communicating substitutions. A named part and an alternate may differ in fit, function, or associated documentation.
Critical-to-quality (CTQ) characteristic. A feature that must meet a requirement because it affects form, fit, function, labeling, packaging, or another documented specification. Each CTQ needs a method, acceptance statement, sampling basis, and record.
Acceptance criteria. Pass/fail rules for an inspection or test. “No defects” is not enough unless defect type, conditions, and disposition are clear. Define cosmetic, functional, packaging, and labeling or artwork requirements.
Incoming inspection. Documented verification of purchased components or materials before production release. Ask what records exist for components central to the quoted configuration, subject to confidentiality.
In-process inspection. Verification during assembly, before final packing. Identify the stage, CTQ, method, sampling plan, criterion, and reaction to a nonconforming result.
Final random inspection (FRI). A check of finished goods from a defined lot before shipment release. State whether sampling is before or after packing, its scope, and how results or rework are documented. FRI is not a substitute for an acceptance plan.
Functional test. A recorded check that a unit performs the agreed function under a defined setup. Specify configuration, fixture, charging source where relevant, firmware revision, and pass/fail result. The test should be reproducible.
Lot traceability. The ability to connect finished units or cases to relevant production, component, inspection, and release records. Ask how the lot identifier appears on the product, package, carton, or shipping documents.
Nonconformance report (NCR). A record of a departure from the approved specification. It should identify the affected scope and revision, immediate containment, disposition, and approver.
Corrective and preventive action (CAPA). A structured response to a confirmed or recurring issue. Request the problem, root-cause approach, correction, preventive action, effectiveness check, owner, and closure evidence. A replacement offer is not CAPA.
Change control. A written process for proposed changes to the BOM, firmware, tooling, artwork, packaging, process, or test method. Define notice, buyer approval, evaluation or validation needs, and the effective lot. The change-control checklist provides a practical starting structure.
Match the evidence to the RFQ risk
This compact table distinguishes a label from useful evidence. It is a buying aid, not a certification framework or legal standard.
| RFQ area | Ask for | A usable response identifies |
|---|---|---|
| Configuration | Controlled drawing, BOM, artwork, and firmware revision | The version being quoted and approved alternates |
| Samples | Evaluation units and sample record | Setup, observations, deviations, and buyer disposition |
| Production controls | CTQ and inspection plan | Stage, method, criterion, sampling approach, and record |
| Release | Final inspection and lot record | Lot identity, result, disposition, and release authority |
| Changes | Change notice and approval log | What changed, affected lots, evaluation, and effective date |
| Issues | NCR/CAPA summary | Containment, disposition, root-cause work, and effectiveness check |
For rechargeable hardware, define evidence around the intended-use system rather than an isolated cell, cable, charger, or device. CPSC recommends that end-product systems—including cells, batteries, chargers, and product—be tested together for appropriate conditions and function. See CPSC’s battery guidance. Ask which system was evaluated and what report or summary a verified buyer may review; this does not establish any product’s status.
Separate sample approval from lot release
Sample review answers whether a specific configuration is acceptable for further evaluation. Production inspection answers whether a defined lot meets the agreed requirements. Keep them distinct. Start with the sample evaluation checklist, then attach the approved results, open items, and revisions to the production RFQ.
For each production lot, define three gates: hold, review, and release. A hold blocks shipment while a stated issue is examined. A review allows named parties to document a disposition. A release confirms that the agreed lot records have been reviewed by the assigned authority. State whether a deviation needs a written waiver and whether rework requires renewed inspection.
FDA’s 2023 Tobacco Product Manufacturing Practice proposal describes a quality-management-system approach with nonconforming-product controls and complaint procedures. It is a proposed rule, not a finalized manufacturing requirement. It illustrates why traceable deviations and complaint records are useful buying topics. Review the Federal Register proposal.
Keep documentation product-specific
Quality records and regulatory status are related but different. A component test record or general supplier statement does not determine the status of a finished configuration.
FDA maintains a current list of e-cigarettes authorized to be sold in the United States. Review the FDA list by product and manufacturer, not a general marketing claim. Verified buyers should request product-specific U.S. regulatory status and relevant documents, then obtain qualified advice. This article is not legal advice.
Import documentation needs the same discipline. CBP has described seizures involving ENDS that lacked required FDA marketing authorization and directs buyers to confirm compliance with applicable import requirements. CBP’s enforcement release is a reminder to identify who supplies and reviews records. An RFQ checklist is not an admissibility determination.
Frequently asked questions
What is the difference between quality control and quality assurance in an RFQ?
Quality control is inspection or testing applied to a unit, component, process, or lot. Quality assurance controls requirements, documents, changes, and corrective actions. QC shows what was checked; QA shows how that check stays repeatable and traceable.
Should a buyer request every supplier record?
No. Request records needed to evaluate the product, configuration, and release gate. Prioritize controlled versions, inspection evidence, lot identity, deviations, and change notices. Agree on access, confidentiality, and retention first.
Does an approved sample automatically approve future production?
No. It establishes a reference for the evaluated revision. Future production still needs the agreed BOM, inspection criteria, traceability, release records, and change-control process.
Can a certificate replace product-specific U.S. documentation?
No. A certificate or general statement may be one input, but it does not determine the status of a particular finished product. Verified buyers should request the relevant product-specific documentation and seek qualified review.
Sources and further reading
- FDA — Manufacturing tobacco products - FDA — E-cigarettes, vapes, and other ENDS authorized by the FDA - Federal Register — Requirements for Tobacco Product Manufacturing Practice, proposed rule - U.S. CPSC — Batteries - U.S. CBP — ENDS import enforcement release
Ready to turn quality terms into an evidence-based RFQ? Request a B2B hardware quote with your controlled configuration, evaluation criteria, and documentation questions.